StoneX Group
SPRO icon

StoneX Group’s Spero Therapeutics SPRO Stock Holding History

StoneX Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$45.8K Buy
+38,241
New +$51.9K ﹤0.01% 1619

Other funds holding SPRO

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Capital Asset Advisory Services
Capital Asset Advisory Services Williamston, Michigan $2.94B AUM 11.83% 1-Year Est. Return
Three Seasons Wealth
Three Seasons Wealth Salt Lake City, Utah $1.12B AUM 34.1% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Ritholtz Wealth Management
Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

StoneX Group's SPRO Position: Q3 2026 in Review

StoneX Group opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 38,241 shares worth $45.8K. The stake represents ﹤0.01% of the portfolio and ranks #1619 among its holdings.

17 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • StoneX Group held 38,241 shares of Spero Therapeutics worth $45.8K as of Q3 2026.
  • Spero Therapeutics was a new StoneX Group position in Q3 2026.
  • Spero Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1619 holding.
  • 17 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.